

Commentary

Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis



Marie Falahee, BSc, PhD¹; Axel Finckh²; Karim Raza^{1,3,4}; and Mark Harrison^{5,6,7}

¹Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; ²Department of Rheumatology, Geneva University Hospital, Geneva, Switzerland; ³Department of Rheumatology, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom; ⁴Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence, MRC Arthritis Research UK Centre for Musculoskeletal Ageing Research, NIHR Biomedical Research Centre, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; ⁵Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada; ⁶Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, British Columbia, Canada; and ⁷Arthritis Research Centre of Canada, Richmond, British Columbia, Canada

ABSTRACT

Effective treatments for rheumatoid arthritis (RA) are available and can lead to remission for some patients, but most patients remain on potentially toxic and expensive medications in the long term. Interest is increasingly turning to the disease phases preceding the development of RA that represent opportunities for preventive interventions. At-risk target populations include individuals with genetic and environmental risk factors, those who have developed systemic autoimmunity, and those who have developed clinically suspect symptoms (eg, arthralgias without synovitis, or an early arthritis). Ongoing prospective studies will inform the development of increasingly accurate predictive tools to identify individuals at risk of developing RA. Furthermore, a range of preventive approaches has been suggested, including lifestyle modification (eg, smoking cessation) and pharmacologic interventions (eg, hydroxychloroquine, methotrexate, abatacept, rituximab) that are currently the subject of randomized controlled trials. As prediction and prevention of RA evolve, it is increasingly likely that individuals at risk (including asymptomatic individuals) may be faced with complex decisions

about whether to accept assessment of their risk status or to take a preventive intervention associated with risk of serious adverse events and uncertain benefit. Acceptance of preventive medication in other contexts can be low. For example, <25% of women at high risk of breast cancer are willing to take preventive hormonal treatments. Actual uptake is lower still. Patients' beliefs and preferences predict treatment uptake and adherence. Before the dream of preventing RA can become reality, health care providers need to understand the perspectives of individuals in the target population and to identify barriers and facilitators for this approach. This commentary reviews what is currently known about the perspectives of patients and individuals at risk about predictive and preventive approaches for RA and identifies gaps to be addressed to inform the development of efficient preventive strategies. (*Clin Ther.* 2019;41:1346–1354) © 2019 Published by Elsevier Inc.

Accepted for publication April 10, 2019

<https://doi.org/10.1016/j.clinthera.2019.04.015>

0149-2918/\$ - see front matter

© 2019 Published by Elsevier Inc.

Keywords: Treatment preferences, rheumatoid arthritis, preventive treatment, risk quantification.

INTRODUCTION

Rheumatoid arthritis (RA) is a common chronic inflammatory disease that affects ~1% of the population. Painful swelling of the joints is typically accompanied by fatigue and depression, and without effective treatment RA can lead to joint destruction and deformity. A number of treatments are now available for patients with RA that can, in some cases, lead to disease remission,¹ but most patients have to remain on potentially toxic and often expensive medications for the long term.² Furthermore, many patients have persistent synovial inflammation despite current therapeutic approaches, and some experience significant extra-articular complications of their RA, including cardiovascular disease and osteoporotic fractures. RA presents a significant burden not only to the individual and his or her families but also to society through increased health care use, disability, and reduced ability to work.^{3,4} Given this, interest is increasingly turning to the phases of disease leading up to the development of RA during which time interventions may be put in place to reduce the risk of RA development.⁵ Accurate identification of individuals at risk of developing RA and effective prevention would likely provide a highly cost-effective strategy for the management of this condition.

European League Against Rheumatism recommendations for prospective studies identify distinct at-risk groups, each of which represents a potential opportunity for preventive intervention. Individuals without RA who are key target groups for preventive approaches may have one or more of the following: (1) genetic risk factors for RA, (2) environmental risk factors for RA, (3) systemic autoimmunity associated with RA (typically associated with the development of rheumatoid factor and/or anti-citrullinated protein/peptide antibodies in the blood), (4) musculoskeletal symptoms suggestive of underlying inflammation but without clinically apparent synovial swelling (also known as clinically suspect arthralgias⁶), or (5) an early arthritis that does not yet fulfil classification criteria for RA.⁷

Predictive tools are currently available that can estimate the risk of RA development for patients in different at-risk phases. For example, tools have been developed to predict RA development in patients with arthralgias and systemic autoimmunity⁸ and undifferentiated arthritis.⁹ These tools include a range of clinical and laboratory variables, including inflammatory markers and the levels of a range of RA-related autoantibodies. Additional predictive variables have also been explored. In patients with arthralgias these include the interferon signature and B-cell signatures^{10–12} and ultrasound findings in the joints.¹³ In patients with unclassified arthritis the presence of ultrasound-defined subclinical synovitis and tenosynovitis has also been investigated.^{14,15} Furthermore, tools are being developed to predict RA in individuals in earlier at-risk stages, for example, in individuals with a family history of RA.¹⁶ Having identified individuals as being at risk of RA, a range of potential approaches may be available to reduce RA risk. These include lifestyle modification and pharmacologic interventions.¹⁷ Of lifestyle modifications, smoking cessation¹⁸ is likely to be most beneficial, but other environmental risk factors have been defined for RA, including silica dust and air pollution, which may also be amenable to environmental modification.¹⁹ Among pharmacologic interventions, the first to be assessed in the context of a clinical trial was intramuscular glucocorticoid, which did not delay arthritis development in patients with autoantibody-positive arthralgias²⁰ but prevented 1 in 10 patients with very early inflammatory polyarthritis from progressing to RA and delayed prescription of disease-modifying antirheumatic drugs (DMARDs).²¹ A trial of rituximab in patients with autoantibody-positive arthralgias and either imaging synovitis or evidence of an acute-phase response on blood tests found that a single infusion of the B-cell-depleting agent significantly delayed the onset of arthritis but did not reduce the number of patients who eventually developed arthritis.²² However, the preventive effect of a number of additional drugs (eg, hydroxychloroquine, atorvastatin, methotrexate, abatacept) is currently being assessed in randomized controlled trials. Further work is needed to define which lifestyle/pharmacologic intervention is most effective in which at-risk stage, with different stages likely to be amenable to different preventive approaches.

IMPORTANCE OF UNDERSTANDING PATIENT PREFERENCES FOR PREVENTIVE APPROACHES

Any preventive treatment will carry risks of adverse events without certainty of preventing the development of RA. Individuals at risk will need to understand their own risk of developing RA and be able to balance it against the risk of drug-related adverse events and the potential benefits of a preventive treatment. Communication of probabilities of risks and benefits is a complex task. Physicians can find it difficult to interpret and communicate risk effectively,²³ and patients struggle to accurately estimate and understand their own risks.²⁴ The manner in which benefits and risks of treatment are presented to patients further influences health decisions.²⁵ The most effective way of conveying risk information may differ according to the individuals' characteristics, such as personality, education, literacy, and numeracy.²⁶

Risk aversion to adverse events has been consistently found to influence the uptake of preventive medication,^{27–29} which can be amplified by a general distrust in medication.³⁰ Effectiveness of treatment seems to have a more variable impact on decision making and depends on the specific context. Participants' willingness to take treatment for cardiovascular prevention changed little with variations in treatment effectiveness.³¹ To take preventive therapy patients may actually require a higher benefit than the medication can achieve.³² Other attributes of preventive treatments, such as the method of administration, may have an important impact on treatment acceptance. Patients evaluating preventive medication for osteoporosis deemed the route of administration to be as important as the likelihood of adverse events.³³

Acceptance of and adherence to preventive interventions for RA will depend not just on the treatment risks and benefits but also on patients' beliefs and preferences. In the context of other diseases, acceptance of preventive medication is low. Fewer than 25% of women at high risk of breast cancer are willing to take preventive hormonal treatment. Effective uptake of medication is even lower²⁸ and predicted by patients' beliefs about medicine.³⁴ Acceptance of treatment for osteoporosis is somewhat higher, but still only about one-half of postmenopausal women would accept

preventive medication at the recommended fracture risk threshold.³⁵

Therefore, an increasing need exists for formative research to be conducted in the potential target populations for preventive intervention, to identify the most important considerations in decision making about treatments, the weight given to various treatment characteristics, and how these vary according to the clinical setting. The remainder of this commentary reviews what is currently known about the perspectives of patients and individuals at risk about predictive and preventive approaches for RA and identifies knowledge gaps that could usefully be addressed to inform the development of ethical and efficient preventive strategies.

PREFERENCES FOR ASSESSMENT OF THE RISK OF DEVELOPING RA

Effective risk stratification is an essential precursor to preventive approaches and an important consideration for proof-of-concept trials because preventive efficacy may be difficult to find in heterogeneous populations.³⁶ Existing models to predict the development of RA in different at-risk groups have discriminative ability,^{8,37} although further evidence from prospective studies is needed to validate and improve risk prediction in preclinical disease stages.^{19,38}

As prediction and prevention of RA evolve, individuals are increasingly likely to be provided with disease risk estimates, whether by health care professionals or by commercial providers (eg, direct-to-consumer genetic testing). Early evidence suggests that a web-based tool providing personalized RA risk education for first-degree relatives of patients with RA increases participants' knowledge of RA risk factors, intentions to change risk-related behaviors, and results in risk-reducing lifestyle changes.^{39,40} However, evidence of the impact of biomarker-based risk information on health behavior change across disease areas is limited.^{41,42} Further research is needed to understand the extent to which inconsistent findings can be explained by heterogeneity in individuals' responses to risk information.

It is important that risk information is communicated in a tailored way that is sensitive to the needs and concerns of those affected.⁴³ Reviews of qualitative studies of stakeholder perceptions of predictive testing in other chronic diseases have highlighted challenging social and ethical issues

associated with the provision of risk information, including concerns about information security and the potential for risk information to have a negative impact.^{44,45} Qualitative studies of the symptoms experienced by patients with a diagnosis of clinically suspect arthralgia found that being at risk of disease progression can have a considerable negative psychological impact.^{46–48} However, a recent randomized controlled trial found that personalized risk communication provided reassurance to first-degree relatives of patients with RA.⁴⁹ It is, therefore, essential to understand the perspectives of all individuals likely to be affected by predictive testing for RA, to identify support needs, and to address preferences for the communication of risk information.

The first study to report on the perspectives of individuals at risk on predictive approaches for RA used qualitative interviews to explore the views of first-degree relatives of patients with existing RA in 3 European countries.⁵⁰ Participants described a lack of awareness about RA and risk factors for RA. Although participants appreciated the value of predictive approaches to facilitate early treatment and preventive intervention, concerns were raised about the accuracy of risk information and the potential for it to have a negative impact on future decision making and the well-being of participants themselves and of other family members.

Reliable access to first-degree relatives is usually indirect and by existing patients with a diagnosis of RA. This in turn depends on patients' willingness to pass on information to their relatives about RA risk. It is, therefore, important to understand patients' perspectives in this context to identify barriers and facilitators to approaches that target first-degree relatives. This was the focus of a UK-based qualitative study⁵¹ that described selective and restricted family communication about RA and further emphasized a demand for informational resources about RA and risk factors for RA to support predictive approaches and communication among family members. Positive attitudes toward risk assessment for their relatives were associated with an expectation that the results would be able to rule in or rule out RA. Negative viewpoints were associated with an appreciation of the probabilistic nature of risk information.

A qualitative interview study of the perspectives of both asymptomatic and symptomatic (clinically

suspect arthralgias without inflammatory arthritis) individuals who had received a positive test result for anti-citrullinated protein antibodies, which was conducted across 3 European countries,⁵² found that symptomatic individuals were more likely to describe feelings of anxiety in response to learning about their risk status and were more receptive to further predictive tests, including tissue sampling. All participants described the need for tailored, accessible informational resources to support predictive and preventive strategies for RA.

Taken together these qualitative studies highlight educational and psychological support needs for the provision of information about future development of RA. Positive viewpoints were associated with highly perceived predictive accuracy and availability of highly effective preventive strategies. This aligns with findings from other chronic diseases.^{53,54} Communication of the imprecision of probabilistic estimates were found to affect decision making about RA treatments,⁵⁵ and effective communication of the accuracy of prognostic models is an important challenge for predictive approaches.⁵⁶

PREFERENCES FOR INTERVENTIONS TO REDUCE RISK OF DEVELOPING RA

Several European qualitative studies have explored preferences relating to preventive interventions for RA of first-degree relatives,^{57–59} patients with RA,^{51,58} and individuals positive for anti-citrullinated protein antibodies without arthritis.⁵²

Lifestyle change was preferred over pharmacologic interventions to reduce RA risk^{51,52,57–59}; however, positive viewpoints were associated with the perspective that any intervention would need to substantially reduce or completely remove their risk of RA. Symptomatic individuals were more likely than asymptomatic individuals to consider preventive medications, subject to their efficacy and side effect profile.⁵²

Some North American indigenous populations have a prevalence of RA estimated to be 5%–7% higher than the general population, and in some populations ~50% of patients have relatives with the disease.^{60,61} A qualitative study of 14 family members of patients with RA in 2 First Nations (Cree and Oji-Cree Nations) in Manitoba suggested that a preventive approach with oral drug intervention with low toxicity, communicated appropriately, within the

context of a research study led by a known and trusted researcher might be acceptable (Smolik I BN, Marra C, El-Gabalawy H. Rheumatoid arthritis risk prevention strategies in First Nations: a qualitative analysis. Unpublished observations.). However, discussions in that study suggested that lifestyle change, for example, smoking cessation, was of limited interest (Smolik I BN, Marra C, El-Gabalawy H. Rheumatoid arthritis risk prevention strategies in First Nations: a qualitative analysis. Unpublished observations.). Fear of drug side effects was highlighted as a central theme, which has also been identified in qualitative studies in Europe.^{57,59}

Further research has involved linked qualitative and quantitative studies to assess the preferences of at-risk populations for preventive treatments for RA. These approaches use qualitative studies to identify key aspects of decision making, which are subsequently used to develop choice-based surveys to quantify preferences.

The first study of this kind was based in Switzerland and included interviews with 20 first-degree relatives of patients with RA. The findings found that, in addition to treatment effectiveness, treatment safety (few adverse effects preferred) and mode of administration (oral tablet taken infrequently at home preferred) are likely to be the key features of a preventive treatment.⁵⁷ The choice-based (best–worst scaling) study derived from this qualitative work confirmed that preventive treatment would have to be targeted to those at high risk of developing RA and offer a high reduction in the risk of developing RA with a low risk of serious side effects for prevention to be acceptable.⁶² Overall, predicted uptake of preventive intervention was low, and results suggested the avoidance of risks of side effects was key to prevention. Some individuals would accept a 10% risk of serious side effects for a highly effective treatment, but most would prefer a moderately effective treatment with a very low risk of serious side effects.⁶²

A similar North American study sought perspectives from patients with RA, first-degree relatives of patients, and rheumatologists to understand what might influence preferences for preventive treatment strategies to inform the development of a choice experiment. The key features identified related to the testing (who recommends the test, accuracy of predictive testing, an individual's risk of developing RA) and the type of preventive treatment used (how a treatment is given,

reduction in the risk of developing RA, risks and seriousness of side effects, strength of supporting evidence of risks and benefits, and other people's opinions of the treatment). Patients and first-degree relatives described wanting to hear the evidence about preventive treatments from multiple trusted sources, including people with the disease and health care professionals.⁵⁸ Preferences elicited from subsequent discrete choice experiments suggested that the decision to take preventive medication will depend primarily on factors other than the reduction in risk of RA.^{63,64} For first-degree relatives of patients this is more likely to be how treatment is taken, the opinion of the health care professionals, and the potential risk and reversibility of side effects.⁶³ Results from studies of patients and rheumatologists also emphasized the primary importance of the shared decision-making process, with results indicating the opinion of the rheumatologist (for patients) and patient (for rheumatologists) as having the strongest influence on preferences.⁶⁴ The results from these studies indicated that of the preventive pharmaceutical treatments currently being evaluated in randomized controlled trials, non-biologic DMARDs such as hydroxychloroquine and potentially methotrexate are much more likely to be acceptable preventive options than biologic DMARDs.^{63,64}

DISCUSSION AND CONCLUSIONS

This commentary has highlighted the importance of understanding the beliefs and preferences of the target population about predictive and preventive approaches to the management of RA and has provided a narrative review of existing studies in this context. A range of qualitative studies have explored the perceptions of at-risk groups on the quantification of an individual's risk of developing RA and have highlighted important informational and support needs that should accompany risk assessment and the challenges of communicating risk effectively and ethically. Quantitative studies are now needed to assess and predict preference heterogeneity in relation to predictive testing and inform the development of tailored strategies. Studies of the perspectives of other stakeholders are also needed to provide a comprehensive understanding and assessment of feasibility and cost effectiveness. For example, it is important to address the perceptions of health care professionals in both primary and secondary care in this context, to understand the feasibility of

implementing potentially complex prediction algorithms in routine clinical care. For the development and assessment of publically funded interventions it can also be argued that the preferences of members of the general public (taxpayers) should also be taken into account.⁶⁵ Furthermore, genetic risk information relating to common multifactorial conditions is increasingly available to consumers outside of traditional health care settings.

Both qualitative and quantitative studies have addressed the preferences of first-degree relatives in relation to preventive treatments for RA and have found that a range of treatment attributes affect decision making, in addition to treatment effectiveness and risks. Further work is needed to identify effective predictors of preference heterogeneity. No quantitative studies have addressed the preferences of seropositive or symptomatic at-risk individuals, despite that these groups are perhaps the most likely candidates for most of the immunomodulatory agents that are currently being evaluated for prevention of RA.

Note that concerns about barriers to access to preventive services were not salient themes in the studies reviewed here. These studies were conducted in Canada and in European countries where there is universal health care, and the findings are unlikely to be representative of populations in, for example, insurance-based health care systems such as the United States where financial barriers to preventive interventions may be a key concern. Further work is needed to explore the impact of political and sociocultural context on perceptions of risk and preventive intervention.

Decisions to take predictive tests or preventive treatments for RA are highly complex. For predictive testing to be worthwhile and RA prevention a reality, preventive interventions will need to offer a favorable benefit–harm trade-off while satisfying the preferences and needs of at-risk individuals. Patients' beliefs are strong predictors of adherence to treatments of RA,^{66,67} and evidence is growing that choice-based preference studies predict actual health behaviors.^{68,69} Understanding the preferences of individuals at risk of RA and other stakeholders for prevention of RA is crucial to facilitate cost-effective clinical translation of investment in prevention research and for efficient and ethical recruitment of participants to preventive trials.

The studies reviewed here are an important step toward achievement of these objectives.

CONFLICTS OF INTEREST

M. Falahee, A. Finckh, and M. Harrison have no conflicts of interest. K. Raza has received honoraria/speaker fees from Abbvie, BMS, Janssen, Lilly, Pfizer, Roche, Sanofi, and UCB and grants from Abbvie and Pfizer. The authors have indicated that they have no other conflicts of interest regarding the content of this article.

ACKNOWLEDGMENTS

This work was partially supported by the Swedish Foundation for Humanities and Social Sciences (Riksbankens Jubileumsfond) [grant number M13–0260:1]. K. Raza is supported by the NIHR Birmingham Biomedical Research Centre. M. Harrison is supported by a Young Investigator Salary Award 2016 from The Arthritis Society (YIS-16-104) and a Michael Smith Foundation for Health Research Scholar Award 2017 (number 16813). All authors contributed equally to the conceptualization, writing, and review of this commentary.

REFERENCES

1. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. *Arthritis Rheum.* 2010;62:3537–3546.
2. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis.* 2017;76:960–977.
3. National Rheumatoid Arthritis Society. *Economic Burden of RA Report*; 2010. https://www.nras.org.uk/data/files/Publications/1_economic_burden_of_ra_final_30_3_10.pdf.
4. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. *Curr Med Res Opin.* 2010;26:77–90.
5. Raza K, Gerlag DM. Preclinical inflammatory rheumatic diseases: an overview and relevant nomenclature. *Rheum Dis Clin North Am.* 2014;40:569–580.

6. van Steenberg HW, Aletaha D, Beart-van de Voorde LJ, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. *Ann Rheum Dis*. 2017;76:491–496.
7. Gerlag DM, Raza K, van Baarsen LG, et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. *Ann Rheum Dis*. 2012;71:638–641.
8. van de Stadt LA, Witte BI, Bos WH, van Schaardenburg D. A prediction rule for the development of arthritis in seropositive arthralgia patients. *Ann Rheum Dis*. 2013;72:1920–1926.
9. van der Helm-van Mil AH, Detert J, le Cessie S, et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. *Arthritis Rheum*. 2008;58:2241–2247.
10. Lubbers J, Brink M, van de Stadt LA, et al. The type I IFN signature as a biomarker of preclinical rheumatoid arthritis. *Ann Rheum Dis*. 2013;72:776–780.
11. Lubbers J, Vosslander S, van de Stadt LA, et al. B cell signature contributes to the prediction of RA development in patients with arthralgia. *Ann Rheum Dis*. 2015;74:1786–1788.
12. Tak PP, Doorenspleet ME, de Hair MJH, et al. Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis. *Ann Rheum Dis*. 2017;76:1924–1930.
13. van der Ven M, van der Veer-Meerkerk M, Ten Cate DF, et al. Absence of ultrasound inflammation in patients presenting with arthralgia rules out the development of arthritis. *Arthritis Res Ther*. 2017;19:202.
14. Filer A, de Pablo P, Allen G, et al. Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. *Ann Rheum Dis*. 2011;70:500–507.
15. Sahbudin I, Pickup L, Nightingale P, et al. The role of ultrasound-defined tenosynovitis and synovitis in the prediction of rheumatoid arthritis development. *Rheumatology (Oxford)*. 2018;57(7):1243–1252.
16. Kolfenbach J, Deane K, Derber L, et al. A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA. *Arthritis Rheum*. 2009;61:1735–1742.
17. Cope AP. Emerging therapies for pre-RA. *Best Pract Res Clin Rheumatol*. 2017;31:99–111.
18. Kallberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. *Ann Rheum Dis*. 2011;70:508–511.
19. Karlson EW, van Schaardenburg D, van der Helm-van Mil AH. Strategies to predict rheumatoid arthritis development in at-risk populations. *Rheumatology (Oxford)*. 2016;55:6–15.
20. Bos WH, Dijkmans BA, Boers M, van de Stadt RJ, van Schaardenburg D. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial. *Ann Rheum Dis*. 2010;69:571–574.
21. Verstappen SMM, McCoy MJ, Roberts C, Dale NE, Hassell AB, Symmons DPM. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. *Ann Rheum Dis*. 2010;69:503–509.
22. Gerlag DM, Safy M, Maijer KI, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study. *Ann Rheum Dis*. 2019;78:179–185.
23. Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S. Helping doctors and patients make sense of health statistics. *Psychol Sci Public Interest*. 2007;8:53–96.
24. Smerecnik CM, Mesters I, Verweij E, de Vries NK, de Vries H. A systematic review of the impact of genetic counseling on risk perception accuracy. *J Genet Couns*. 2009;18:217–228.
25. Carling CL, Kristoffersen DT, Montori VM, et al. The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial. *Plos Med*. 2009;6, e1000134.
26. Peters E, Hart PS, Fraenkel L. Informing patients: the influence of numeracy, framing, and format of side effect information on risk perceptions. *Med Decis Making*. 2011;31:432–436.
27. Waters EA, Weinstein ND, Colditz GA, Emmons K. Explanations for side effect aversion in preventive medical treatment decisions. *Health Psychol*. 2009;28:201–209.
28. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. *J Clin Oncol*. 2010;28:3090–3095.
29. Marshall IJ, Wolfe CD, McKeivitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. *BMJ*. 2012;345, e3953.
30. Scoville EA, Ponce de Leon Lovaton P, Shah ND, Pencille LJ, Montori VM. Why do women reject bisphosphonates for osteoporosis? A videographic study. *PLoS One*. 2011;6:e18468.
31. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. *Arch Intern Med*. 2011;171:923–928.
32. Llewellyn-Thomas HA, Paterson JM, Carter JA, et al. Primary prevention drug therapy: can it meet patients' requirements for reduced risk? *Med Decis Making*. 2002;22:326–339.

33. Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. *Patient Educ Couns.* 2007;65:237–244.
34. Thorneloe RJ, Horne R, Side L, et al. Beliefs about medication and uptake of preventive therapy in women at increased risk of breast cancer: results from a multicenter prospective study. *Clin Breast Cancer.* 2019;19:e116–e126.
35. Neuner JM, Schapira MM. Patient perceptions of osteoporosis treatment thresholds. *J Rheumatol.* 2014;41:516–522.
36. Burgers LE, Allaart CF, Huizinga TWJ, van der Helm-van Mil AHM. Brief report: clinical trials aiming to prevent rheumatoid arthritis cannot detect prevention without adequate risk stratification: a trial of methotrexate versus placebo in undifferentiated arthritis as an example. *Arthritis Rheumatol.* 2017;69:926–931.
37. Sparks JA, Chen CY, Jiang X, et al. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. *Ann Rheum Dis.* 2015;74:1522–1529.
38. Boeters DM, Raza K, Vander Helm-van Mil AHM. Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art. *RMD Open.* 2017;3, e000479.
39. Prado MG, Iversen MD, Yu Z, et al. Effectiveness of a web-based personalized rheumatoid arthritis risk tool with or without a health educator for knowledge of rheumatoid arthritis risk factors. *Arthritis Care Res (Hoboken).* 2018;70:1421–1430.
40. Sparks JA, Iversen MD, Yu Z, et al. Disclosure of personalized rheumatoid arthritis risk using genetics, biomarkers, and lifestyle factors to motivate health behavior improvements: a randomized controlled trial. *Arthritis Care Res.* 2018;70:823–833.
41. Hollands CJ, French DP, Griffin SJ, et al. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. *BMJ.* 2016;352:i1102.
42. Li SX, Ye Z, Whelan K, Truby H. The effect of communicating the genetic risk of cardiometabolic disorders on motivation and actual engagement in preventative lifestyle modification and clinical outcome: a systematic review and meta-analysis of randomised controlled trials. *Br J Nutr.* 2016;116:924–934.
43. Lautenbach DM, Christensen KD, Sparks JA, Green RC. Communicating genetic risk information for common disorders in the era of genomic medicine. *Annu Rev Genomics Hum Genet.* 2013;14:491–513.
44. Bayliss K, Raza K, Simons G, et al. Perceptions of predictive testing for those at risk of developing a chronic inflammatory disease: a meta-synthesis of qualitative studies. *J Risk Res.* 2018;21:167–189. <https://www.tandfonline.com/doi/abs/10.1080/13669877.2015.1119183>.
45. Falahee M, Simons G, Raza K, Stack RJ. Healthcare professionals' perceptions of risk in the context of genetic testing for the prediction of chronic disease: a qualitative metasynthesis. *J Risk Res.* 2018;21:129–166. <https://www.tandfonline.com/doi/abs/10.1080/13669877.2016.1153503>.
46. Stack RJ, van Tuyl LH, Sloots M, et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. *Rheumatology (Oxford).* 2014;53:1646–1653.
47. van Tuyl LH, Stack RJ, Sloots M, et al. Impact of symptoms on daily life in people at risk of rheumatoid arthritis. *Musculoskeletal Care.* 14:169–173.
48. Newsum EC, van der Helm-van Mil AH, Kaptein AA. Views on clinically suspect arthralgia: a focus group study. *Clin Rheumatol.* 2016;35:1347–1352.
49. Marshall AA, Zaccardelli A, Yu Z, et al. Effect of communicating personalized rheumatoid arthritis risk on concern for developing RA: a randomized controlled trial. *Patient Educ Couns.* 2018;102(5):976–983.
50. Stack RJ, Stoffer M, Englbrecht M, et al. Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study. *BMJ Open.* 2016;6, e010555.
51. Falahee M, Simons G, Buckley CD, Hansson M, Stack RJ, Raza K. Patients' perceptions of their relatives' risk of developing rheumatoid arthritis and of the potential for risk communication, prediction, and modulation. *Arthritis Care Res (Hoboken).* 2017;69:1558–1565.
52. Mosor E, Stoffer-Marx M, Steiner G, et al. I would never take preventive medication! Perspectives and information needs of people who underwent predictive tests for rheumatoid arthritis. *Arthritis Care Res.* 2019. <https://doi.org/10.1002/acr.23841>.
53. Collins J, Ryan L, Truby H. A systematic review of the factors associated with interest in predictive genetic testing for obesity, type II diabetes and heart disease. *J Hum Nutr Diet.* 2014;27:479–488.
54. Konda V, Huo D, Hermes G, Liu M, Patel R, Rubin DT. Do patients with inflammatory bowel disease want genetic testing? *Inflamm Bowel Dis.* 2006;12:497–502.
55. Bansback N, Harrison M, Marra C. Does introducing imprecision around probabilities for benefit and harm influence the way people value treatments? *Med Decis Making.* 2016;36:490–502.

56. Hunter DJ. Uncertainty in the era of precision medicine. *N Engl J Med*. 2016;375:711–713.
57. Novotny F, Haeny S, Hudelson P, Escher M, Finckh A. Primary prevention of rheumatoid arthritis: a qualitative study in a high-risk population. *Jt Bone Spine*. 2013;80:673–674.
58. Munro S, Spooner L, Milbers K, Hudson M, Koehn C, Harrison M. Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis. *BMC Rheumatol*. 2018;2:18.
59. Simons G, Stack RJ, Stoffer-Marx M, et al. Perceptions of first-degree relatives of patients with rheumatoid arthritis about lifestyle modifications and pharmacological interventions to reduce the risk of rheumatoid arthritis development: a qualitative interview study. *BMC Rheumatol*. 2018;2:31.
60. Barnabe C, Jones CA, Bernatsky S, et al. Inflammatory arthritis prevalence and health services use in the First Nations and non-First Nations populations of Alberta, Canada. *Arthritis Care Res (Hoboken)*. 2017;69:467–474.
61. Oen K, Robinson DB, Nickerson P, et al. Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes. *J Rheumatol*. 2005;32:983.
62. Finckh A, Escher M, Liang MH, Bansback N. Preventive treatments for rheumatoid arthritis: issues regarding patient preferences. *Curr Rheumatol Rep*. 2016;18:51.
63. Harrison MSL, Hudson M, Koehn C, Finckh A, Bansback N. Preventing rheumatoid arthritis: north American perspectives on the risk of developing the disease and of potential preventative interventions. *Arthritis Rheumatol*. 2017;69(suppl 10). <https://acrabstracts.org/abstract/preventing-rheumatoid-arthritis-north-american-perspectives-of-patients-and-first-degree-relatives-on-the-risk-of-developing-the-disease-and-of-potential-preventative-interventions/>.
64. Harrison MBN, Spooner L, Koehn C, Hudson M. Preventing rheumatoid arthritis (pre-RA): preferences of potential recipients, patients and health care professionals for preventive treatment. *J Rheumatol*. 2018;45. <https://doi.org/10.3899/jrheum.180300>.
65. De Wit GA, Busschbach JJ, De Charro FT. Sensitivity and perspective in the valuation of health status: whose values count? *Health Econ*. 2000;9:109–126.
66. Hope HF, Bluett J, Barton A, Hyrich KL, Cordingley L, Verstappen SM. Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. *RMD Open*. 2016;2, e000171.
67. Smolen JS, Gladman D, McNeil HP, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. *RMD Open*. 2019;5, e000585.
68. Quaife M, Terris-Prestholt F, Di Tanna GL, Vickerman P. How well do discrete choice experiments predict health choices? A systematic review and meta-analysis of external validity. *Eur J Health Econ*. 2018;19:1053–1066.
69. Mohammadi T, Bansback N, Marra F, et al. Testing the external validity of a discrete choice experiment method: an application to latent tuberculosis infection treatment. *Value Health*. 2017;20:969–975.

Corresponding author. E-mail: m.falahee@bham.ac.uk